The GPC3 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HT29 human colorectal adenocarcinoma cell line, designed for loss-of-function studies of the GPC3 gene. This polyclonal pool is generated by CRISPR-mediated gene disruption, offering a heterogeneous knockout model that captures genetic diversity while avoiding clonal selection artifacts, suitable for population-level functional analyses.
The HT29 parental cell line is an epithelial model isolated from a primary colorectal adenocarcinoma of a female patient, widely employed in colorectal cancer research. These cells retain key intestinal epithelial features and responsiveness to differentiation and proliferative signals, providing a physiologically relevant background for studying oncogenic pathways and therapeutic interventions.
GPC3 encodes a cell surface heparan sulfate proteoglycan that critically modulates Wnt and Hedgehog signaling. It acts as a co-receptor, competing with Frizzled for Wnt3a and attenuating ??-catenin/TCF-mediated transcription of downstream targets such as Cyclin D1 and c-Myc. In the Hedgehog pathway, GPC3 facilitates binding of Sonic Hedgehog and internalization of the Patched receptor, thereby regulating Gli transcription factors and target genes including PTCH1 and GLI1. GPC3 also interacts with FGF2 and the LRP6 co-receptor, integrating growth factor and morphogen signals to control cell fate decisions.
In HT29 colorectal cancer cells, GPC3 disruption is anticipated to dysregulate both Wnt and Hedgehog pathways, potentially enhancing ??-catenin activity and Gli-mediated transcription. These alterations may shift the balance between proliferation and apoptosis, influencing tumorigenic properties such as migration, invasion, and anchorage-independent growth. This model therefore enables dissection of GPC3’s context-dependent roles in colorectal tumorigenesis and its interplay with upstream regulators ??-catenin/TCF and Hedgehog/Gli signaling.
This polyclonal knockout cell population is a versatile platform for cancer biology and drug development studies. It supports proliferation (MTT, BrdU), apoptosis (Annexin V), migration, and colony formation assays, as well as chemosensitivity testing with agents including 5-fluorouracil. Pathway perturbations can be assessed via Western blotting for GPC3 and downstream targets, RT-qPCR for Wnt/Hedgehog target genes (e.g., Cyclin D1, PTCH1), and immunofluorescence for ??-catenin localization. RNA-seq enables global transcriptomic profiling, and the model facilitates biomarker discovery and signaling mechanism studies. For more information, contact Ascent Research.
